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Abstract
Purpose Pro-inflammatory cytokines such as Interleukin-17A (IL17A) and Interleukin-32 (IL32), known to enhance natural killer and T cell responses, are also elevated in human malignancies and linked to poor clinical outcomes. To address this paradox, we evaluated relation between IL17A and IL32 expression and other inflammation-and T cell response-associated genes in breast tumors. Methods TaqMan-based gene expression analysis was carried out in seventy-eight breast tumors. The association between IL17A and IL32 transcript levels and T cell response genes, ER status as well as lymph node status was also examined in breast tumors from TCGA dataset. Results IL17A expression was detected in 32.7% ER-positive and 84.6% ER-negative tumors, with higher expression Electronic supplementary material The online version of this article (doi:10.1007/s00432-017-2431-5) contains supplementary material, which is available to authorized users.
Introduction
Association of inflammatory responses with the initiation, promotion, and progression of malignancies is well established (Coussens and Werb 2002) . This cancerrelated inflammation (CRI) is orchestrated by cytokines, chemokines, and growth factors secreted by different cellular constituents of the tumor and the tumor microenvironment. While some of these molecules may represent effector immune responses against the growing neoplasm, their prolonged presence along with pro-inflammatory signals arising from tumor cells heightens the level of inflammation in the tumor milieu (Colotta et al. 2009 ). This in turn facilitates tumor survival and dissemination via increased tumor vasculature and suppression of effector anti-tumor immune responses (Balkwill et al. 2005; Ben-Baruch 2006; Colotta et al. 2009 ).
Inflammation has also been linked to poor prognosis in breast cancer patients (Ham and Moon 2013) highlighting the need for better understanding of its influence on tumor escape and invasion. With the presence of distinct biological and molecular subtypes that have varied prognostic implications (Sims et al. 2007) , breast cancer provides a natural model to examine such associations. Hence, our study focussed on comparison of expression of primary mediators of inflammation and Th1 response in these breast cancer subtypes. Among them, expression levels of Interleukin 17A (IL17A) and Interleukin 32 (IL32), two dominant pro-inflammatory cytokines in CRI, were highlighted and assessed in clinical context.
Over-expression of IL17A, an inflammatory molecule primarily of lymphoid origin, has been associated with many allergic and autoimmune diseases (Xu and Cao 2010) . Despite being extensively studied in various malignancies, influence of IL17A on disease prognosis remains ambiguous (Murugaiyan and Saha 2009; Wilke et al. 2011) . Association of IL17A with inflammation, invasiveness, angiogenesis, and recruitment of immunosuppressive myeloid-derived stem cells (MDSCs) or tumorigenic neutrophils at the tumor site has been reported (Numasaki et al. 2003; Zhu et al. 2008; He et al. 2010; Cochaud et al. 2013; Benevides et al. 2015) . These observations support correlation between IL17A expression and poor prognosis (Zhang et al. 2009; Chen et al. 2010 Chen et al. , 2013 Liu et al. 2011) . Conversely, IL17A has also been shown to suppress tumor growth by inducing antitumor cytotoxic T-and T-helper (Th1/Th17) cell immune responses (Yamamoto et al. 2009; Martin-Orozco et al. 2009; Phan-Lai et al. 2016) .
IL32, on the other hand, is expressed by multiple cell types and is known to potently induce expression of other inflammatory molecules such as TNF alpha (TNFα). But like IL17A, its over-expression has been implicated in the emergence of inflammatory diseases (Joosten et al. 2013) . IL32 expression has also been shown to be associated with poor prognosis in various cancers (Sorrentino and Di Carlo 2009; Lee et al. 2012; Guenin et al. 2014 ). Interestingly, due to its pro-apoptotic influence, IL32 was identified as a tumor suppressor in prostate cancer (Majid et al. 2010) while its role in cervical cancer remains ambiguous (Lee et al. 2011; Punt et al. 2015) . Incidentally, some studies also point towards its contribution to anti-mycobacterial and anti-viral responses (Montoya et al. 2014; Zhou and Zhu 2015) supported by its ability to enhance function of various immune response-associated cell types (Jung et al. 2011; Park et al. 2012; Yun et al. 2013) .
IL17A and IL32 also share signaling intermediates (Turner-Brannen et al. 2011 ) which may have a bearing upon their ability to contribute to effector immunity in a variety of settings. Expression of immune response-associated genes has been shown to enhance prognostic power of clinical markers independent of proliferative gene signatures (Haibe-Kains et al. 2010) . These considerations provide strong rationale for analyzing gene expression profiles of these two cytokines with respect to T-cell response markers. Association between IL17A and IL32 expression levels with hormone receptor and regional lymph node status of breast cancer patients was also studied to explore possible relevance of these mediators of inflammation to disease prognosis. Finally, data from TCGA database were analyzed to further examine trends of expression of T-cell response-associated genes in the context of intra-tumoral IL17A and IL32 expression patterns.
Materials and methods
Sample collection
One hundred and sixty breast tumor specimens were collected from tumor repositories at TMH and ACTREC from 2009 to 2012 with the approval of the ethics committee at TMH. The inclusion criteria were, (1) confirmed diagnosis of primary breast cancer (Invasive Ductal Carcinoma), and (2) tumor size ≤5 cm. The exclusion criteria were (1) excision biopsy, (2) therapy prior to surgery, and (3) strong history of autoimmune disorders. Tumors collected were either stored in liquid nitrogen or in RNAlater™ (Ambion, Inc., Austin, TX, USA). Of these, 81 specimens were found to have tumor cell content greater than 60% and were processed further for RNA extraction. Gene expression data for all markers studied were available for 78 tumors. Clinical information of the patients including age at diagnosis, lymph nodes status, and the hormone receptor expression profiles of the tumors was collected from the medical records of individual patients (Table 1) .
RNA extraction, cDNA synthesis, and real-time PCR
Total RNA was extracted from the selected tissues either by TRIzol (TRI Reagent, Ambion Inc.)-based method or using RNA extraction columns from mirVana™ miRNA Isolation kit (Ambion Inc.) as per the recommended protocol. RNA was quantified using NanoDrop ND 2000 spectrophotometer (NanoDrop Inc., Wilmington, DE, USA) and the quality was assessed on agarose gels. First-strand synthesis was performed using high-capacity cDNA synthesis kit [Applied Biosystems (ABI), Foster City, CA, USA]. Transcript levels of IL17A, IL32, and related markers (Supplementary Table  S1 ) were analyzed using TaqMan assays (ABI). Expression levels were normalized using PUM1 as the endogenous control/housekeeping gene (McNeill et al. 2007 ). Real-time PCR was performed on the ABI Prism 7900 platform. Due to inconsistent RNA yields from normal breast tissues, we used commercially available normal breast-derived RNA preparation (Human Breast Total RNA, Ambion Inc.) as a calibrator to compute fold change (2 −ΔΔCt method).
Analysis of TCGA expression dataset
mRNA expression data and corresponding clinical information of breast cancer samples were obtained (April 2015) from The Cancer Genome Atlas (TCGA) data repository. Level 3 expression data of IL17A and IL32 were extracted for further analysis. The cohort (n = 1041) was divided into three classes on the basis of IL32 expression data; IL32_hi (n = 260), IL32_moderate (n = 521), and IL32_ lo (n = 260)) using the 25th-75th percentile criteria for sample division. For IL17A, tumor samples were divided into positive (n = 131) and negative (n = 910) groups on the basis of presence or absence of the transcript for the cytokine. Available ER/PR and lymph node status was correlated with gene expression patterns.
Statistical analysis
Differential expression of quantitative variables and their statistical analysis was performed using non-parametric Mann-Whitney U test. Each marker was classified into high and low producers on the basis of median fold value for that marker, in all tumors or specific subgroups. Difference in distribution of high and low producers for each marker across ER subtypes and lymph node status was tested for significance using Chi-square analysis. Correlations between expressions of all genes were estimated using Pearson's correlation. Differences with p values ≤0.05 were considered to be statistically significant. Statistical analysis was performed using SPSS (SPSS for Windows v16.0; SPSS Inc., Chicago, IL, USA) and graphs were generated using GraphPad Prism Software (Version 5.01, GraphPad, San Diego, CA).
Results
Clinicopathological features of patients with primary breast cancer
With the exception of two tumors, all the collected specimens represented infiltrating ductal carcinomas (IDCs) with majority (>75%) belonging to grade III disease. In the randomly selected and eligible 78 breast tumor specimens, 52 (67%) were ER positive (Table 1) . ERBB2 expression was seen at equal frequency (~30%) within the tumors from both ER subtypes. Age distribution was also comparable in patients with ER-positive and ER-negative tumors. Sixty-three percent of ER-positive tumor-bearing patients were lymph node positive while this was true for 37% of ER-negative patients.
IL17A transcript expression is highly variable in human breast tumors
IL17A transcripts were undetected in the commercially available normal breast-derived RNA preparation (see "Materials and methods"). ER-negative subgroup contained a relatively higher fraction of IL17A-positive tumors as compared to ER-positive subgroup (84 vs. 32%, p < 0.05, Table 3 ). Additionally, IL17A mRNA levels detected in ER-negative tumors were significantly higher compared to those in ER-positive tumors (median fold, 26 and 7, respectively, p < 0.01; Table 2 ). IL32 transcript is expressed at elevated levels in majority of breast tumors IL32 transcripts were ubiquitously expressed in all breast tumors studied. Sixty-eight percent tumors (53/78) displayed two-fold or higher IL32 expression compared to normal tissue (data not shown). As in case of IL17A, IL32 transcript levels were higher in ER-negative tumors. Accordingly, the median fold value for IL32 in ER-negative tumors was over three times higher compared to values seen in ER-positive tumors (8.7 vs. 2.5 fold, p < 0.01, Table 2 ).
ER-negative tumors are characterized by higher expression of genes representing mediators of inflammation
ER-negative tumors also showed significantly higher levels of expression of genes associated with inflammation and Th1 responses such as CCL5, GNLY, IL8, IL12, IL21, IL23, and TBX21 as compared to their ER-positive counterparts (p < 0.05, Table 2 ). Of these, GNLY, IL8, IL12, IL21, and IL23 along with IL17A and IL32 showed at least three-fold difference in expression across the ER-receptor subtypes.
IL17A and IL32 levels have common associations with expression of IFNγ, CCL5, GNLY, TBX21, IL21, and IL23
Expression of CCL2, CCL5, IL21, IL23, IFNγ, and IL12 moderately correlated with IL17A (Pearson's correlation, r > 0.4, p ≤ 0.01). Similar trends were seen for correlation between IL32 expression and IFNγ, IL12, IL21, IL23, TNF, CCL2, and CCL5 levels (Supplementary Tables S2a  and S2b ). These correlations were further assessed by comparing expression levels of different markers in tumors grouped on the basis of high and low transcript levels of IL17A or IL32 (Mann-Whitney U test). In case of IL17A, the classification of tumors was made on the basis of presence or absence of IL17A transcripts in these tumors. This analysis showed that TBX21, CCL5, GNLY, IL8, IL12, IL21, IL23, and IL32 were significantly over-expressed in IL17A-positive tumors as compared to IL17A-negative tumors (p < 0.05, Fig. 1a) . Similarly, CCL2, CCL4, CCL5, GNLY, IFNγ, IL21, IL23, and TBX21 transcript levels were significantly higher in high IL32 expressing tumors in comparison to low IL32-expressing tumors (p < 0.05, Fig. 1b) . Thus, IL17A and IL32 have common expression correlation with CCL5, TBX21, GNLY, IL21, and IL23. Influence of high IL17A and IL32 expression levels on lymph node status may depend on ER subtype
Expression levels of all markers were compared in the context of lymph node status of the patients (Mann-Whitney U test). Of 52 ER-positive tumor-bearing patients, 33 (63%) were lymph node positive. In this subtype, higher levels of IL8 and IL32 were significantly associated with lymph node-positive status. On the other hand, of the 26 patients with ER-negative tumors, 17 (63%) had lymph node-negative status. In this subtype, higher expression levels of CCL3, CCL5, IL1B, IL17A, and TNFα were associated with lymph node-negative status (p < 0.05, Fig. 2 ).
ER-negative tumors expressing high levels of IL17A and IL32 are predominantly associated with lymph node-negative status For combined expression of both these cytokines in relation to lymph node status, four different expression profiles were generated (Table 3 ). In ER-negative subset, tumors positive for IL17A expression were predominantly from lymph node-negative patients (16/22) when compared to the IL17A-deficient tumors (1/4) (72 vs. 25%, p < 0.05). IL17A-positive tumors with high IL32 expression had the highest frequency of lymph node-negative patients (9/11, 82%) suggesting strong association of combined expression of both these cytokines with lymph node-negative status in ER-negative subset. This observed synergistic effect of high IL17A and IL32 expression on lymph node-negative status of patients was also seen when such analysis was extended to IL17A-positive-only tumors (on the basis of their IL17A median fold value, tumors were classified as
IL17A
hi and IL17A lo ). Herein, ER-negative tumors with IL17A hi IL32 hi profile were found to belong to lymph node-negative patients (6/6, Supplementary Table S3) .
However, such synergistic effect was not observed in ER-positive subset, wherein tumors with high IL32 expression belonged predominantly to lymph nodepositive patients (19/26) as opposed to the low IL32 expressing tumors (14/26), although this trend was not statistically significant (73 vs. 53%, p = 0.12). In this group of tumors, frequencies of lymph node-positive and lymph node-negative patients were comparable in IL17A pos IL32 hi and IL17A neg IL32 hi subgroups (Table 3) . Markers associated with expression of IL17A and IL32, respectively. Tumors were classified into high and low producers for IL17A and IL32 using median fold values for these cytokines as classifier. The other markers studied were then compared across the IL17A and IL32 subgroups and tested for statistical significance using MannWhitney U test. *Significance at p < 0.05 levels while **significance at p < 0.01 level Fig. 2 Markers differentially expressed across lymph node-positive and lymph node-negative patients in both ER subtypes of breast cancer. Mann-Whitney U test was used to compute statistical significance. *Significance at p < 0.05 levels while **significance at p < 0.01 level
Increased IL17A and IL32 levels are associated with high expression of T-cell response genes
Earlier data analysis indicated that high IL32 expression may increase risk for lymph node metastasis in patients with ER-positive tumors. Interestingly, tumors with higher expression of IL17A or IL32 were also characterized by higher levels of GNLY and TBX21 (Fig. 1) further justifying the assessment of expression patterns of the selected markers in the context of different combinations of IL17A and IL32 expression levels. Distinctly higher levels and frequency of T-cell response-associated genes such as IL12, TBX21, and GNLY expression were noted in 'IL17A-positive, IL32-high' group of tumors (Fig. 3) . These tumors were also characterized by strikingly higher expression levels of IL23, CCL4, CCL5, and CCL2.
Analysis of TCGA data supports the association between IL17A and IL32 expression patterns and expression of T-cell response-associated genes
Our real-time data also revealed much higher ΔCt values for IL17A as compared to those of IL32 and other , clearly highlighting association between high levels of these two inflammatory cytokines and T-cell responses. In each case, the differences in the expression levels of the markers analyzed were statistically significant when compared with the first group (p < 0.001; Fig. 4) .
Discussion
With the link between inflammation and cancer established, next challenge lies in deducing contributions of different cytokines and associated pathways to cancer-related inflammation and anti-cancer immunity. In this study, using naturally defined subsets of hormone receptor-positive and hormone receptor-negative breast cancers, we examined expression profiles of a group of cytokines and chemokines that are considered to be major players in cancer-related inflammation. In view of recent interests in the role of IL17A and IL32 in cancer, we focussed on their expression patterns in breast cancer and their association with expression of genes that mediate inflammation and T-cell response. IL17A and IL32 levels were also correlated with lymph node status of patients, used as a surrogate marker for prognosis (Carter et al. 1989; Jatoi et al. 1999) . The strikingly higher expression of genes associated with inflammation observed in ER-negative tumors is in agreement with previous data reported by Chavey et al. (2007) . Contrasting frequencies and levels of IL17A expression in different ER subtypes found in our study are compatible with data from studies employing immunohistochemistry (Droeser et al. 2012; Chen et al. 2013) . Furthermore, similar trends were also seen in breast tumors from the TCGA database with nearly three-fold higher frequency of IL17A expressing tumors in ERnegative tumors compared to the ER-positive ones (25 vs. 9%, p < 0.05). Higher IL32 expression observed in ERnegative tumors than ER-positive tumors is in concurrence with high levels of this cytokine reported in basallike breast cancers (Player et al. 2014) .
Strong association of IL17A levels with IL21 and IL23 expression is in accordance with the role of these two cytokines in IL17A induction and maintenance of IL17A-producing cell populations (Chen et al. 2010 ). IL21 and IL23 expression also correlated significantly with IL32 levels which may represent a common signaling cascade shared by this cytokine with IL17A (Turner-Brannen et al. 2011) . Furthermore, high IL17A and IL32 expression positively correlated with IFNγ, CCL5, GNLY, and TBX21 levels, which collectively represent Th1/CTL response genes, an observation primarily seen in ER-negative subgroup (Supplementary Table 2a, b) . Thus, ERnegative tumors expressing high IL17A and IL32 levels were characterized by strong combined Th1/CTL and Th17 signatures, an effect that may suggest the role of IL17A in augmenting effector anti-tumor T-cell-mediated immune responses (Benchetrit et al. 2002; Ankathatti Munegowda et al. 2011; Nunez et al. 2013 ). This is further highlighted by higher frequency of lymph node-negative patients in ER-negative tumors expressing high levels of both cytokines (Supplementary Table 3) .
Expression of high IL32 levels in ER-positive tumors, on the other hand, was associated with positive lymph node status, independent of IL17A expression. This effect can be attributed to relatively lower frequency and levels of IL17A expression in this tumor subset and ensuing lack of synergism between IL17A and IL32 in mounting effector anti-tumor immune responses. Additionally in ER-positive tumors, IL32 and IL8 were significantly over-expressed in patients with positive lymph node status as compared to their lymph node-negative counterparts. IL32 is known to be an inducer of TNFα (Kim et al. 2005) , a phenomenon that is also reflected in our analysis (Supplementary Tables S2b) . Potent proinflammatory influence of this cytokine could promote angiogenesis and invasiveness via IL8 and TNFα (Shoda et al. 2006; Nold-Petry et al. 2014) and could contribute to the observed positive lymph node status in patients with ER-positive breast tumors. Association between high levels of IL32 with lymph node positivity has also been reported in other malignancies (Sorrentino and Di Carlo 2009) .
The proposed synergism between IL17A and IL32 towards enhancing Th1 responses was further validated in breast tumors from the TCGA cohort. In agreement with our observations, similar trends were seen in the TCGA samples wherein transcript levels of Th1 response genes were the highest in tumors with the IL32 Figure  S2) . Furthermore, marginally higher frequency of lymph node negativity in IL17A hi IL32 hi compared to that in IL17A neg IL32 hi in ER-negative subgroup (58 vs. 55%) was seen in breast cancer patients from the TCGA cohort. Such a trend was not seen in case of ER-positive tumors (Supplementary Table 4 ) implying a probable subtype-specific effect of synergy between the two cytokines on the disease prognosis. However, it must be noted that the hormone receptor status was not known for nearly 25% of these patients. Concurrently, our data are compatible with the reported association between T-cell response signatures and favorable prognosis in breast cancer patients with ER-negative tumors (Reyal et al. 2008; Rody et al. 2009; Teschendorff et al. 2010) . The possibility that high levels of IL17A and IL32 in ER-negative tumors from lymph node-negative patients seen in this study would have an impact on the disease prognosis is supported by observation documenting significantly better overall survival (80% at 5 years) in such patients compared to their lymph nodepositive counterparts (65% or less; p < 0.001) (HernandezAya et al. 2011) .
Thus, briefly, our analysis highlighted several important aspects of gene expression patterns in breast cancers such as, (a) significant differences between expression levels of inflammation-associated genes, especially, IL17A and IL32 in the two subtypes studied, (b) association between high IL17A and IL32 expression and expression of T-cell response-associated genes, and (c) association of high IL17A levels and lymph node-negative status in ER-negative tumors. In addition, the reported associations between IL23 expression with both IL17A and IL32, between IL32 and TNFα, as well as association of high IL32 levels with lymph node metastasis in ER-positive tumors were also reflected in our results.
In our immunohistochemical analysis of paraffinembedded tissues from representative ER-negative and ER-positive tumors (data not shown), we were able to detect only sporadically IL17A-positive cells (Chen et al. 2010; Zhu et al. 2008) . Ubiquitous expression of IL32 in normal as well as malignant breast tissues was seen with low to moderate staining in tumor cells as well as in lymphoid compartment. Staining patterns in hormone receptorpositive and hormone receptor-negative tumors were comparable. Immunohistochemical detection of cytokines and interleukins is known to be a daunting task since a majority of them are secreted. In addition, the choice of primary antibodies and presence of different isoforms of the target molecules may contribute to the variations in staining patterns. Hence, profiling of gene expression patterns remains a sensitive and efficient method to study the interplay between multiple immunological parameters in tumor tissues (Rody et al. 2009; Reyal et al. 2008; Teschendorff et al. 2010) , which is also emphasized by recent studies in cervical (Omrane and Benammar-Elgaaied 2015) and colorectal cancers (Punt et al. 2015) .
In view of various roles assigned to different isoforms of IL 32 (Choi et al. 2009; Heinhuis et al. 2012; Kang et al. 2012; Park et al. 2015) and the suggested influence of combinations of IL17A and IL32 expression on the lymph node status in patients studied herein, we examined expression of four IL32 isoforms (IL32-β, -γ, -δ, -ε) in breast cancer subtypes in the context of IL17A expression. Significantly lower levels of IL32γ transcripts (p < 0.05; Mann-Whitney U test) were seen in ER-positive tumors that also expressed IL17A transcripts (Supplementary Figure S3A) . Lower expression of IL32γ also seen in ER-positive tumors with high IL32 transcripts levels (Supplementary Figure S3A) may be due to the higher frequency of IL17A-positive tumors in this group compared to tumors with lower IL32 expression. Interestingly, in contrast to IL32γ isoform, levels of other three isoforms were significantly higher in former group of tumors (p < 0.05). The possibility of inverse association between IL17A and IL32γ expression was further supported by similar observation in ER-negative tumors wherein tumors with higher IL17A levels compared to those with lower IL17A transcripts were characterized by reduced expression of IL32γ (Supplementary Figure S3B) .
Incidentally, IL32γ has been described as the most potent inflammatory isoform of the cytokine (Choi et al. 2009; Heinhuis et al. 2012) and was found to induce several-fold increase in IDO expression by various subtypes of leukocytes (Smith et al. 2011 ). This mechanism was proposed to contribute to immune-suppression in HIV patients (El-Far et al. 2016) . Similar mechanism may operate in tumors with high expression of IL32 and IL17A as these tumors also displayed higher levels of T-cell response-associated genes and negative lymph node status.
Skewed frequencies of lymph node-positive and lymph node-negative patients in both ER subsets represents a limitation of the present study that arose in the course of random selection of eligible specimens. An excellent correlation between gene expression patterns of IL17A, IL32, and their related markers as well as overall compatibility of our data with those reported by other studies and from the TCGA cohort rules out the effect of skewed distribution of lymph node metastases on the inferences drawn. The role of other IL17 family members (IL17B-F) in the observed phenomenon remains unexplored. Same may be true of IL32 isoforms (Kang et al. 2014) , especially in view of lack of direct measurement of levels IL32α isoform which has been shown to modulate NFkB expression in hepatocellular carcinoma cells (Kang et al. 2012 ) and a variety of interactions between the IL32 isoforms and effects of IL32 heterodimers .
It is interesting to note that despite highly inflammatory microenvironment in ER-negative tumors several studies have shown the existence of strong TH1/Tc responses in these tumors with their positive impact on the disease outcome (Reyal et al. 2008; Rody et al. 2009; Teschendorff et al. 2010) . Data obtained in the present study are also in accordance with reports that highlight the potential of these two cytokines to enhance T-cell responses and point towards a synergistic effect of these pro-inflammatory entities in generating anti-tumor T-cell response. Thus, the findings provide possible basis for association between T-cell response gene signature and disease prognosis in ER-negative breast tumors. Effects of pleiotropic cytokines can vary depending upon the site of the inflammation owing to the microenvironment (Joshi et al. 2014) , due to synergistic, antagonistic, or balancing effects which play an important part in influencing disease outcome. The suggested synergy between IL17A and IL32 highlights one such phenomenon and provides basis to the reported association between strong immune response signatures and better prognosis in hormone receptor-negative breast cancers. As revealed by the analysis of IL32 isoforms, the observed effect may operate via suppression of inflammatory isoform of IL32 (IL32γ) contributing to an enhanced T-cell metagene signature and subsequent lower disease spread.
To summarize, our results indicate that IL17A and IL32 together boost T-cell metagene signature in both ER-positive and ER-negative tumors. High expression of the two cytokines was associated with lymph node negativity in ER-negative subgroup but not in the ER-positive subgroup. This disparity may arise from the differences in the levels 1 3 of expression of these two cytokines in ER-negative as against ER-positive tumors, implying a 'threshold' effect.
